Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
1 Primary · 15 Secondary · Reporting Duration: Randomization up to ≤30 days after last dose
375 Total Participants · 3 Treatment Groups
Primary Treatment: furmonertinib 240 mg · No Placebo Group · Phase 3
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: